Table 5.
Population sequencing analysis of GT1a NS3-R155K replicon cells selected following treatment with of rIFN-λ1or rIFN-α in combination with DAAs
| Regimen | Treatment (EC50 multiple) | Amino acid change at the indicated position |
|||||
|---|---|---|---|---|---|---|---|
| NS3 R155 | NS5A |
||||||
| K24 | M28 | Q30 | L31 | Y93 | |||
| Mono | Untreated | K | K/T | ||||
| ASV (10) | K | ||||||
| DCV (10) | K | K/T | Q/H | ||||
| rIFN-α (10) | K | ||||||
| rIFN-λ1 (10) | K | ||||||
| Dual | ASV + rIFN-α (2.5) | K | K/T | ||||
| ASV + rIFN-α (5) | K | ||||||
| ASV + rIFN-λ1 (2.5) | K | K/T | |||||
| ASV + rIFN-λ1 (5) | K | ||||||
| ASV + rIFN-λ1 (10) | K | ||||||
| ASV + rIFN-λ1 (30) | K | ||||||
| DCV + rIFN-α (2.5) | K | K/T/E | H/Q | ||||
| DCV + rIFN-α (5) | K | F/Y | |||||
| DCV + rIFN-λ1 (5) | K | M/T | Y/H | ||||
| ASV + DCV (2.5) | K | K/T | Q/H/R | ||||
| ASV + DCV (5) | K | K/T | Q/H/R | L/M | |||
| ASV + DCV (10) | K | Q/H/R | L/M | ||||
| ASV + DCV (30) | K | H/Q | |||||
| Triple | ASV + DCV + rIFN-α (1) | K | |||||
| ASV + DCV + rIFN-λ1 (1) | K | ||||||
| ASV + DCV + rIFN-λ1 (2.5) | K | K/T | |||||